Breaking: Alvotech Shares Dips 5% On Earnings Report Shares of Alvotech (NASDAQ: NASDAQ:ALVO ) saw a noteworthy downtick of 5% amidst earnings report yesterday after market close. Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimm
3.5 SEK
−2.58 B SEK
5.44 B SEK
108.97 M
About Alvotech
Sector
Industry
CEO
Vilhelm Róbert Wessman
Website
Headquarters
Luxembourg
Founded
2021
ISIN
SE0025011463
FIGI
BBG01TYGX737
Alvotech breaking out towards 16-18 levelAfter price broke out of the bearish line before and after making a hammer, it started a retracement.
My assumption is it will eventually retest the Weekly EMA 10 levels, which will serve as support.
Going long there (with the SL below the EMA 10) is a conservative way to enter the bullish trend
Alvotech Nears U.S. Approval for Biosimilar MedicinesIn a significant development for Alvotech (NASDAQ: NASDAQ:ALVO ), a global biotech company specializing in biosimilar medicines, the conclusion of the U.S. Food and Drug Administration (FDA) reinspection of its facility in Iceland has brought the company one step closer to achieving regulatory appr
See all ideas